Home / For You / For Clinicians
AL amyloidosis is one of the most underdiagnosed conditions in medicine. This page is designed to help you recognize it earlier, work up the diagnosis efficiently, and refer patients to specialist care when needed.
The average time from first symptoms to confirmed diagnosis is 2 to 3 years. AL amyloidosis is frequently attributed to more common conditions — heart failure to hypertension, proteinuria to diabetes, neuropathy to idiopathic causes. A high index of suspicion in atypical presentations is the single most important factor in reducing diagnostic delay.
The key question to ask when something doesn't fit: could this be amyloid?
Thickened LV walls on echocardiogram without a history of hypertension or aortic stenosis should prompt an immediate amyloidosis workup. Low-voltage ECG in the presence of increased wall thickness is a particularly specific finding. Strain imaging showing an apical-sparing pattern is highly characteristic of cardiac amyloidosis.
Heavy proteinuria without a history of diabetes or known glomerular disease warrants a serum and urine free light chain assessment. AL amyloidosis is present in a significant proportion of patients referred for unexplained nephrotic syndrome. Early renal involvement is often asymptomatic beyond proteinuria.
Bilateral carpal tunnel syndrome — particularly in patients without an obvious occupational or anatomical cause — is a recognized early manifestation of AL amyloidosis. Autonomic neuropathy, painful small fiber neuropathy, and neuropathy resistant to standard treatments should also prompt consideration of an amyloid screen.
Macroglossia, particularly with lateral tongue scalloping, is highly specific for systemic AL amyloidosis. Periorbital purpura occurring spontaneously or after minor trauma — the so-called "raccoon eyes" — is another near-pathognomonic sign. The combination of both should be considered diagnostic until proven otherwise and biopsy arranged immediately.
Early referral to an amyloidosis specialist center significantly improves outcomes. Specialist centers offer multidisciplinary assessment, access to clinical trials including NXC-201 CAR-T therapy, and the experience to stage and treat complex presentations that generalist settings may not encounter frequently.
If you have a patient with confirmed or strongly suspected AL amyloidosis, do not wait for organ function to decline before referring. Earlier referral means more treatment options.